{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:01:57Z","timestamp":1786982517520,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01635-4","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T11:35:25Z","timestamp":1733398525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The T cell-mediated tumor killing patterns revealed tumor heterogeneous and proposed treatment recommendation in ovary cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"Xinglin","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beining","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cungeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"1635_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20126089","author":"I Saani","year":"2023","unstructured":"Saani I, Raj N, Sood R, Ansari S, Mandviwala HA, Sanchez E, et al. Clinical challenges in the management of malignant ovarian germ cell tumours. Int J Environ Res Public Health. 2023. https:\/\/doi.org\/10.3390\/ijerph20126089.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"1635_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1635_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191\u2013226. https:\/\/doi.org\/10.6004\/jnccn.2021.0007.","journal-title":"J Natl Compr Canc Netw"},{"key":"1635_CR4","doi-asserted-by":"publisher","first-page":"175883592412332","DOI":"10.1177\/17588359241233225","volume":"16","author":"A Ghose","year":"2024","unstructured":"Ghose A, McCann L, Makker S, Mukherjee U, Gullapalli SVN, Erekkath J, et al. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Ther Adv Med Oncol. 2024;16:17588359241233224. https:\/\/doi.org\/10.1177\/17588359241233225.","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"1635_CR5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.annonc.2020.05.019","volume":"31","author":"J Millstein","year":"2020","unstructured":"Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020;31(9):1240\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.019.","journal-title":"Ann Oncol"},{"key":"1635_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191912057","author":"A Ghose","year":"2022","unstructured":"Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, et al. Hereditary ovarian cancer: towards a cost-effective prevention strategy. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph191912057.","journal-title":"Int J Environ Res Public Health"},{"key":"1635_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2021.102045","volume":"75","author":"N Pavlidis","year":"2021","unstructured":"Pavlidis N, Rassy E, Vermorken JB, Assi T, Kattan J, Boussios S, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75: 102045. https:\/\/doi.org\/10.1016\/j.canep.2021.102045.","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"1635_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304. https:\/\/doi.org\/10.3322\/caac.21559.","journal-title":"CA Cancer J Clin"},{"key":"1635_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19138113","author":"S Shah","year":"2022","unstructured":"Shah S, Cheung A, Kutka M, Sheriff M, Boussios S. Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph19138113.","journal-title":"Int J Environ Res Public Health"},{"key":"1635_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371: m3773. https:\/\/doi.org\/10.1136\/bmj.m3773.","journal-title":"BMJ"},{"issue":"8","key":"1635_CR11","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345. https:\/\/doi.org\/10.1038\/nm.3909.","journal-title":"Nat Med"},{"key":"1635_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093125","author":"D Baci","year":"2020","unstructured":"Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, et al. The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: a focus on innate immunity cells as therapeutic effectors. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21093125.","journal-title":"Int J Mol Sci."},{"issue":"25","key":"1635_CR13","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1911361.","journal-title":"N Engl J Med"},{"issue":"10304","key":"1635_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X.","journal-title":"Lancet"},{"issue":"6","key":"1635_CR15","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234(6):8509\u201321. https:\/\/doi.org\/10.1002\/jcp.27782.","journal-title":"J Cell Physiol"},{"key":"1635_CR16","doi-asserted-by":"publisher","unstructured":"Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359(6377):770\u20135. https:\/\/doi.org\/10.1126\/science.aao1710.","DOI":"10.1126\/science.aao1710"},{"issue":"5","key":"1635_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tips.2019.03.005","volume":"40","author":"BJ Drapkin","year":"2019","unstructured":"Drapkin BJ, Farago AF. Unexpected synergy reveals new therapeutic strategy in SCLC. Trends Pharmacol Sci. 2019;40(5):295\u20137. https:\/\/doi.org\/10.1016\/j.tips.2019.03.005.","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"1635_CR18","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","volume":"184","author":"ND Mathewson","year":"2021","unstructured":"Mathewson ND, Ashenberg O, Tirosh I, Gritsch S, Perez EM, Marx S, et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021;184(5):1281-98 e26. https:\/\/doi.org\/10.1016\/j.cell.2021.01.022.","journal-title":"Cell"},{"key":"1635_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.688215","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou X, Du J, Liu C, Zeng H, Chen Y, Liu L, et al. A pan-cancer analysis of CD161, a potential new immune checkpoint. Front Immunol. 2021;12: 688215. https:\/\/doi.org\/10.3389\/fimmu.2021.688215.","journal-title":"Front Immunol"},{"issue":"20","key":"1635_CR20","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btz210.","journal-title":"Bioinformatics"},{"key":"1635_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinf. 2010;11:367. https:\/\/doi.org\/10.1186\/1471-2105-11-367.","journal-title":"BMC Bioinf"},{"key":"1635_CR22","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81114","author":"Z Liu","year":"2022","unstructured":"Liu Z, Weng S, Dang Q, Xu H, Ren Y, Guo C, et al. Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer. Elife. 2022. https:\/\/doi.org\/10.7554\/eLife.81114.","journal-title":"Elife"},{"key":"1635_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.828330","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Xu H, Weng S, Ren Y, Han X. Stemness refines the classification of colorectal cancer with stratified prognosis, multi-omics landscape, potential mechanisms, and treatment options. Front Immunol. 2022;13: 828330. https:\/\/doi.org\/10.3389\/fimmu.2022.828330.","journal-title":"Front Immunol"},{"key":"1635_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235951","author":"Q Yi","year":"2022","unstructured":"Yi Q, Pu Y, Chao F, Bian P, Lv L. ACAP1 deficiency predicts inferior immunotherapy response in solid tumors. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14235951.","journal-title":"Cancers"},{"key":"1635_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.682084","volume":"8","author":"Z Liu","year":"2021","unstructured":"Liu Z, Lu T, Wang L, Liu L, Li L, Han X. Comprehensive molecular analyses of a novel mutational signature classification system with regard to prognosis, genomic alterations, and immune landscape in glioma. Front Mol Biosci. 2021;8: 682084. https:\/\/doi.org\/10.3389\/fmolb.2021.682084.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"1635_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812-30 e14. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023.","journal-title":"Immunity"},{"issue":"11","key":"1635_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001195","volume":"2","author":"Y Hoshida","year":"2007","unstructured":"Hoshida Y, Brunet JP, Tamayo P, Golub TR, Mesirov JP. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS ONE. 2007;2(11): e1195. https:\/\/doi.org\/10.1371\/journal.pone.0001195.","journal-title":"PLoS ONE"},{"issue":"9","key":"1635_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9): e107468. https:\/\/doi.org\/10.1371\/journal.pone.0107468.","journal-title":"PLoS ONE"},{"key":"1635_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964190","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Liu Z, Gao J, Liu X, Weng S, Guo C, et al. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma. Front Immunol. 2022;13: 964190. https:\/\/doi.org\/10.3389\/fimmu.2022.964190.","journal-title":"Front Immunol"},{"issue":"1","key":"1635_CR30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12905-024-03100-4","volume":"24","author":"F Ferrari","year":"2024","unstructured":"Ferrari F, Giannini A. Approaches to prevention of gynecological malignancies. BMC Womens Health. 2024;24(1):254. https:\/\/doi.org\/10.1186\/s12905-024-03100-4.","journal-title":"BMC Womens Health"},{"key":"1635_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741.","journal-title":"Annu Rev Pathol"},{"issue":"28","key":"1635_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202202797","volume":"9","author":"Y Yang","year":"2022","unstructured":"Yang Y, Zhao T, Chen Q, Li Y, Xiao Z, Xiang Y, et al. Nanomedicine strategies for heating \u201cCold\u201d ovarian cancer (OC): next evolution in immunotherapy of OC. Adv Sci (Weinh). 2022;9(28): e2202797. https:\/\/doi.org\/10.1002\/advs.202202797.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1635_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12943-021-01367-x","volume":"20","author":"M Herrera","year":"2021","unstructured":"Herrera M, Berral-Gonzalez A, Lopez-Cade I, Galindo-Pumarino C, Bueno-Fortes S, Martin-Merino M, et al. Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients. Mol Cancer. 2021;20(1):73. https:\/\/doi.org\/10.1186\/s12943-021-01367-x.","journal-title":"Mol Cancer"},{"issue":"2","key":"1635_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","volume":"35","author":"N Zhang","year":"2011","unstructured":"Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011;35(2):161\u20138. https:\/\/doi.org\/10.1016\/j.immuni.2011.07.010.","journal-title":"Immunity"},{"key":"1635_CR35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190218","author":"AA Abdul Pari","year":"2021","unstructured":"Abdul Pari AA, Singhal M, Augustin HG. Emerging paradigms in metastasis research. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20190218.","journal-title":"J Exp Med"},{"issue":"9","key":"1635_CR36","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","volume":"24","author":"A Luengo","year":"2017","unstructured":"Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol. 2017;24(9):1161\u201380. https:\/\/doi.org\/10.1016\/j.chembiol.2017.08.028.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"1635_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cmet.2018.09.002","volume":"29","author":"G Gentric","year":"2019","unstructured":"Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, et al. PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers. Cell Metab. 2019;29(1):156\u20137310. https:\/\/doi.org\/10.1016\/j.cmet.2018.09.002.","journal-title":"Cell Metab"},{"issue":"4","key":"1635_CR38","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e104","volume":"35","author":"C Perrone","year":"2024","unstructured":"Perrone C, Angioli R, Luvero D, Giannini A, Di Donato V, Cuccu I, et al. Targeting BRAF pathway in low-grade serous ovarian cancer. J Gynecol Oncol. 2024;35(4): e104. https:\/\/doi.org\/10.3802\/jgo.2024.35.e104.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"1635_CR39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12967-020-02491-w","volume":"18","author":"X Wang","year":"2020","unstructured":"Wang X, Duanmu J, Fu X, Li T, Jiang Q. Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment. J Transl Med. 2020;18(1):324. https:\/\/doi.org\/10.1186\/s12967-020-02491-w.","journal-title":"J Transl Med"},{"issue":"1","key":"1635_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13048-019-0494-4","volume":"12","author":"L Zhang","year":"2019","unstructured":"Zhang L, Luo M, Yang H, Zhu S, Cheng X, Qing C. Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients. J Ovarian Res. 2019;12(1):19. https:\/\/doi.org\/10.1186\/s13048-019-0494-4.","journal-title":"J Ovarian Res"},{"issue":"15","key":"1635_CR41","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1158\/1078-0432.CCR-17-3862","volume":"24","author":"D Hao","year":"2018","unstructured":"Hao D, Liu J, Chen M, Li J, Wang L, Li X, et al. Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemosensitivity. Clin Cancer Res. 2018;24(15):3560\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3862.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1635_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203\u201313. https:\/\/doi.org\/10.1056\/NEJMoa020177.","journal-title":"N Engl J Med"},{"issue":"8","key":"1635_CR43","doi-asserted-by":"publisher","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","volume":"28","author":"K Odunsi","year":"2017","unstructured":"Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28(8):viii1\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx444.","journal-title":"Ann Oncol"},{"key":"1635_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003329","author":"R Muthuswamy","year":"2021","unstructured":"Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, et al. CXCR6 by increasing retention of memory CD8(+) T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003329.","journal-title":"J Immunother Cancer"},{"key":"1635_CR45","doi-asserted-by":"publisher","first-page":"175883592093761","DOI":"10.1177\/1758835920937612","volume":"12","author":"B Zhao","year":"2020","unstructured":"Zhao B, Zhao H, Zhao J. Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 2020;12:1758835920937612. https:\/\/doi.org\/10.1177\/1758835920937612.","journal-title":"Ther Adv Med Oncol"},{"key":"1635_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics9020055","author":"S Boussios","year":"2019","unstructured":"Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, et al. PARP inhibitors in ovarian cancer: the route to \u201cIthaca.\u201d Diagnostics. 2019. https:\/\/doi.org\/10.3390\/diagnostics9020055.","journal-title":"Diagnostics."},{"issue":"4","key":"1635_CR47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1635_CR48","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s40425-019-0810-y","volume":"7","author":"Q Wang","year":"2019","unstructured":"Wang Q, Zhang J, Tu H, Liang D, Chang DW, Ye Y, et al. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. J Immunother Cancer. 2019;7(1):334. https:\/\/doi.org\/10.1186\/s40425-019-0810-y.","journal-title":"J Immunother Cancer"},{"key":"1635_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/bs.ircmb.2019.07.005","volume":"348","author":"F Kotsias","year":"2019","unstructured":"Kotsias F, Cebrian I, Alloatti A. Antigen processing and presentation. Int Rev Cell Mol Biol. 2019;348:69\u2013121. https:\/\/doi.org\/10.1016\/bs.ircmb.2019.07.005.","journal-title":"Int Rev Cell Mol Biol"},{"key":"1635_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"CB Crayne","year":"2019","unstructured":"Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119. https:\/\/doi.org\/10.3389\/fimmu.2019.00119.","journal-title":"Front Immunol"},{"issue":"3","key":"1635_CR51","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2018.03.052","volume":"173","author":"AC Bester","year":"2018","unstructured":"Bester AC, Lee JD, Chavez A, Lee YR, Nachmani D, Vora S, et al. An integrated genome-wide CRISPRa approach to functionalize lncRNAs in drug resistance. Cell. 2018;173(3):649-64 e20. https:\/\/doi.org\/10.1016\/j.cell.2018.03.052.","journal-title":"Cell"},{"key":"1635_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb0737","author":"Z Yang","year":"2021","unstructured":"Yang Z, Wang W, Zhao L, Wang X, Gimple RC, Xu L, et al. Plasma cells shape the mesenchymal identity of ovarian cancers through transfer of exosome-derived microRNAs. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abb0737.","journal-title":"Sci Adv"},{"key":"1635_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27144478","author":"S Peter","year":"2022","unstructured":"Peter S, Alven S, Maseko RB, Aderibigbe BA. Doxorubicin-based hybrid compounds as potential anticancer agents: a review. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27144478.","journal-title":"Molecules."},{"issue":"19","key":"1635_CR54","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-17-3588","volume":"24","author":"HY Lim","year":"2018","unstructured":"Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, et al. Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma. Clin Cancer Res. 2018;24(19):4650\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3588.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1635_CR55","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2174\/1568009623666230209121732","volume":"23","author":"F Aliyuda","year":"2023","unstructured":"Aliyuda F, Moschetta M, Ghose A, Sofia Rallis K, Sheriff M, Sanchez E, et al. Advances in ovarian cancer treatment beyond PARP inhibitors. Curr Cancer Drug Targets. 2023;23(6):433\u201346. https:\/\/doi.org\/10.2174\/1568009623666230209121732.","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01635-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01635-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01635-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T12:05:32Z","timestamp":1733400332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01635-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1635"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01635-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"753"}}